The Firm is reviewing claims on behalf of Interstitial Cystitis (IC) patients who took the prescription drug Elmiron and now may be suffering from a severe eye disease called maculopathy or has suffered vision impairment as a result. If you developed malculopathy or a vision impairment and took Elmiron, give Elmiron Lawyer Timothy L. Miles a call today, you could be entitled to significantly compensation if you meet the Elmiron Lawsuit Criteria and file an Elmiron Eye Damage Lawsuit.
Read on for answers to frequently asked questions about an Elmiron Eye Damage Lawsuit.
Elmiron Lawyer Timothy L. Miles a call today, you could be entitled to significantly compensation if you meet the Elmiron Lawsuit Criteria
What is Elmiron?
Since 1996, millions of patients have been prescribed Elmiron in order to treat their interstitial cystitis (IC), otherwise known as painful bladder syndrome. But there is now reason to believe that this drug may cause a serious eye condition in those taking it, one that may result in blindness.
This condition is a form of maculopathy – the degeneration of the macula, the central part of the retina. Maculopathy’s first symptoms are blurred vision, dark spots, trouble focusing, and other impairments: as it progresses, it may lead to total blindness. As the evidence has piled up, the manufacturer of Elmiron – Janssen Pharmaceuticals – has failed to warn the public about these risks. Millions of people are taking a drug that may one day rob them of their vision, and an untold number may have already suffered serious health conditions. Elmiron eye damage lawsuits on behalf of the injured have already begun claiming their maculopathy was caused by Elmiron. If you or a loved one took Elmiron and has since been diagnosed with maculopathy, or vision impairment you may be eligible for compensation. Contact an Elmiron Lawyer today to have your case reviewed for free and see if you meet the Elmiron lawsuit criteria. Is maculopathy caused by Long-Term Use of Elmiron?
n 2018, researchers at the Emory Eye Center at the Emory School of Medicine in Atlanta alerted the public that taking Elmiron is linked to the retinal condition, maculopathy. Pentosan polysulfate sodium can cause severe vision problems and side effects, including interstitial cytitis, and even blindness.
Nieraj Jain, M.D., of Emory Eye Center in Atlanta, Ga., reported that six Elmiron patients who had been taking Elmiron for about 15 years had developed unusual changes in their macula. Because nothing in the patients’ medical history or diagnostic tests explained the subtle, but striking pattern of abnormalities, Dr. Jain and his colleagues raised a warning flag that long-term use of Elmiron may damage the retina. The retina is a thin layer of tissue that lines the back of the eye on the inside. It is located near the optic nerve. The retina receives light that the lens has focused and converts the light into neural signals. It then sends these signals on to the brain for visual recognition All patients in the study reportedly showed signs of retinal disease and that the youngest patient in the study was diagnosed with interstitial cystitis at 23 years of age. That patient began taking the medication daily and began showing visual symptoms by the age of 30. In addition, three ophthalmologists conducted a review of patients at Kaiser Permanente in Northern California and found that approximately one-quarter of patients with significant exposure to Elmiron showed definite signs of eye damage. It also found the medication could potentially be linked to retinal conditions, such as age-related macular degeneration or pattern dystrophy. Patients who have used or are using the pentosan polysulfate sodium drug Elmiron are advised to be screened by ophthalmologists if they are experiencing any unusual eye symptoms. They are also advised to cease pentosan therapy if eye disease is present. What Are the Symptoms of Elmiron Related Retinal Maculopathy?
A newly discovered condition has come to light, and it is presently unknown how many symptoms there actually are, or how serious this can end up being for those suffering from it.
The currently known symptoms associated with this eye condition include:
What Is the Elmiron Lawsuit Criteria?
The current Elmiron lawsuit criteria require:
The criteria are based upon the medical studies linking the drug to eye disease and vision impairment, including interstitial cytitis and maculopathy. However, there may be exceptions to the Elmiron lawsuit criteria. There may be other eye damage claims available for you to pursue. Call an Elmiron Lawyer today to See if You Meet the Elmiron Lawsuit Criteria
If you were diagnosed with maculopathy or vision impairment caused by Elmiron, contact an Elmiron Lawyer today as you most likely meet the Elmiron lawsuit criteria and are eligible to file an Elmiron lawsuit and possibly recover substantial compensation. The call is free and so is the fee unless we will you case. So, call today and see what an Elmiron lawyer can do for you.
So, give us a call today or submit the free case evaluation form. Timothy L. Miles, Esq.Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, and more. Please visit our website. Comments are closed.
|
AuthorTimothy L. Miles Archives
September 2024
Categories
All
|
Hours |
|